An observational study in Sickle Cell Disease, sponsored by National Heart, Lung, and Blood Institute (NHLBI). Enrolling by invitation at 2 sites in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by National Heart, Lung, and Blood Institute (NHLBI) · Observational
Among 61 studies in Anemia, Sickle Cell by National Heart, Lung, and Blood Institute (NHLBI) — 5 open to participants now, 13 under way, none of them phase 3. Anemia, Sickle Cell · National Heart, Lung, and Blood Institute (NHLBI).
Among the 61 studies in Anemia, Sickle Cell by National Heart, Lung, and Blood Institute (NHLBI), this one is the 3rd largest by planned enrollment of the 21 observational ones that give a count, is one of 2 that started in 2002, is one of 29 observational ones, and was the 23rd registered.
1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.
Browse Anemia, Sickle Cell studies →5 of the 61 studies in Anemia, Sickle Cell by National Heart, Lung, and Blood Institute (NHLBI) are open now, in 1 country. Recruiting first, the newest first:
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–90
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 4–65
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–65
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–100
By country, each count listing its studies:
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 17 · Phase 3 4
First in 1977; this study’s year is marked. 2 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 100 across 296 observational studies indexed under Anemia, Sickle Cell.
Median enrollment 30 across the 27 interventional studies, 119 across the 21 observational. Of the 47 that completed or were terminated, 9 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Heart, Lung, and Blood Institute (NHLBI) is the lead sponsor of 1,143 studies on the registry; 71 are open to participants now.
Of its 58 completed or terminated interventional studies of FDA-regulated products, 51 (88%) have results posted.
3 of the studies in Anemia, Sickle Cell by National Heart, Lung, and Blood Institute (NHLBI) that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07566494National Heart, Lung, and Blood Institute (NHLBI)Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease | 2027-04-27 |
| NCT05904093National Heart, Lung, and Blood Institute (NHLBI)Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease | 2027-05-14 |
| NCT05675436National Heart, Lung, and Blood Institute (NHLBI)Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease | 2027-10-27 |
Among the 61 studies in Anemia, Sickle Cell by National Heart, Lung, and Blood Institute (NHLBI), from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The collection of human specimens from both patients and healthy volunteers is necessary for the development of laboratory assays to further basic and clinical research studies. This protocol defines the purposes for which specimens will be collected and establishes general conditions under which sample collection will be performed.
The collection of human specimens from both patients and healthy volunteers is necessary for the development of laboratory assays to further basic and clinical research studies. This protocol defines the purposes for which specimens will be collected and establishes general conditions under which sample collection will be performed.
Normal subjects, Male/Female
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Males or females of age 18 years and older can be included in the study.
EXCLUSION CRITERIA:
Individuals without sickle cell disease or other chronic anemias who wish to donate blood will be excluded if the is less than 10 g/dL for women or less than 12g/dL for men.
Individuals with sickle cell disease or other chronic anemias will be excluded from donating blood samples if the hemoglobin is less than 6 g/dL.
A participant s most recent CBC result, obtained in the past 12 months, will be used to determine eligibility.
There are no exclusion criteria for participants donating urine.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinical Center Patients, Healthy Volunteers
evaluating the role of nitric oxide, inflammatory mediators, and endothelial function in inflammatory diseases of the vasculature such as sickle cell disease, coronary artery disease, pulmonary vascular or advanced lung disease, malaria, and sep...
Started Nov 2002 (actual).
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Heart, Lung, and Blood Institute (NHLBI) →